EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy for downstaging of locally advanced mismatch repair deficient colorectal cancer: A prospective institutional case series

Maeve A O'Neill, Emily C Harrold, Charles Gillham, Ciara Ryan, Brian J Mehigan, Cian Muldoon, Petra Martin, Cillian Clancy, Dara O Kavanagh, David J Gallagher, John O Larkin, Gráinne O'Kane und 2 weitere

European Journal of Surgical Oncology · 2026

DOI: 10.1016/j.ejso.2025.111166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Maeve A O'Neill und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, St. James's Hospital/Trinity College Dublin, Dublin, Ireland. Electronic address: maeveoneill@rcsi.ie. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, Adenocarcinoma. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Mismatch repair deficiency (MMRd) is a tumour-agnostic biomarker predicting response to immune checkpoint inhibition (ICI). Microsatellite unstable (MSI-H) colorectal cancers (CRC) display poor response to 5-Fluorouracil-based chemotherapy. ICIs demonstrate benefit in stage IV disease, but data on neoadjuvant ICI remain limited. METHODS: Prospective case series evaluating early outcomes of downstaging PD-1 inhibition for locally unresectable ± oligometastatic MMRd colorectal adenocarcinomas. Primary endpoints are complete clinical response, conversion to curative resection or disease progression. Ethical approval was granted by the institution's ethical review board. RESULTS: From October 2022-September 2024, ten patients started downstaging ICI, including six right-sided, one left-sided and three rectal tumours. Median age was 59 (IQR 54-68). One patient had stage II, six stage III and three stage IV disease. All had threatened surgical margin necessitating downstaging. Three patients with rectal cancer also received radiotherapy, and two commenced systemic chemotherapy before switching to ICI. Five patients required a defunctioning stoma. Median follow-up was 21.5 months (IQR 16-26). Objective response rate (RECIST 1.1) was 9/10. Six of ten tumours were resected, with complete pathological response (pCR) in four. Three others underwent non-operative management, following a complete or near-complete clinical response (cCR/ncCR). Nine of ten patients are alive. Four patients had grade 2/3 toxicity, while four developed a clinically significant treatment-related stricture, with one perforation. CONCLUSION: We report promising downstaging and pCR/cCR rate of ICI for initially-unresectable MMRd CRC. ICI-first can permit curative resection, with risk of local complication from significant treatment response. Larger, multi-centre studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsAdenocarcinomaHumansAgedMiddle AgedProspective StudiesMaleFemaleNeoplasm StagingNeoadjuvant TherapyDNA Mismatch RepairMicrosatellite InstabilityBrain NeoplasmsNeoplastic Syndromes, Hereditary

Stichwörter der Autor:innen

Colorectal cancerDownstagingImmune checkpoint inhibitionMicrosatellite instabilityMismatch repair deficiencyUnresectable

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Surgery, St. James's Hospital/Trinity College Dublin, Dublin, Ireland. Electronic address: maeveoneill@rcsi.ie.
  • Department of Medical Oncology, St. James's Hospital/Trinity College Dublin, Dublin, Ireland.
  • Department of Radiation Oncology, St. James's Hospital/Trinity College Dublin, Dublin, Ireland.
  • Department of Histopathology, St. James's Hospital/Trinity College Dublin, Dublin, Ireland.
  • Department of Surgery, St. James's Hospital/Trinity College Dublin, Dublin, Ireland.
  • Department of Medical Oncology, Midland Regional Hospital, Tullamore, Co. Offaly, Ireland.

Zitieren

APA

O'Neill, M. A., Harrold, E. C., Gillham, C., Ryan, C., Mehigan, B. J., Muldoon, C., Martin, P., Clancy, C., Kavanagh, D. O., Gallagher, D. J., Larkin, J. O., O'Kane, G., McCormick, P. H., & Kelly, M. E. (2026). Immunotherapy for downstaging of locally advanced mismatch repair deficient colorectal cancer: A prospective institutional case series. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.111166

Vancouver

O'Neill MA, Harrold EC, Gillham C, Ryan C, Mehigan BJ, Muldoon C, et al. Immunotherapy for downstaging of locally advanced mismatch repair deficient colorectal cancer: A prospective institutional case series. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2025.111166

BibTeX
@article{ONeill2026,
  author = {O'Neill, Maeve A and Harrold, Emily C and Gillham, Charles and Ryan, Ciara and Mehigan, Brian J and Muldoon, Cian and Martin, Petra and Clancy, Cillian and Kavanagh, Dara O and Gallagher, David J and Larkin, John O and O'Kane, Gráinne and McCormick, Paul H and Kelly, Michael E},
  title = {Immunotherapy for downstaging of locally advanced mismatch repair deficient colorectal cancer: A prospective institutional case series},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1016/j.ejso.2025.111166}
}
Kostenlos starten →